Preliminary findings of the PREDICT study suggest that the DUET Ultrasound Enthesitis Score may improve the confidence with ...

Patients with ankylosing spondylitis taking secukinumab saw improvements in enthesitis, and some achieved complete resolution, suggesting the drug could be a viable option for patients intolerant of ...

In this cross-sectional study, Poggenborg and colleagues evaluated the ability of an emerging imaging technology, "whole-body" MRI (WBMRI), to detect enthesitis in patients with psoriatic arthritis ...

Patients with psoriatic arthritis with enthesitis are more likely to have severe disease than patients without enthesitis, and they and their physicians are less likely to be satisfied with their ...

Certain new concepts in joint disease are gradually being introduced and treated. One such painful condition is named ‘enthesitis’. Although not exactly a type of ‘arthritis’, enthesitis could be ...

Treatment with guselkumab (Tremfya) was effective in resolving enthesitis among patients with psoriatic arthritis (PsA), a post-hoc analysis of two phase III trials found. At week 24, 45% of patients ...

Please provide your email address to receive an email when new articles are posted on . Treatment with guselkumab results in higher enthesitis resolutions rates at week 24, with maintenance of those ...

Please provide your email address to receive an email when new articles are posted on . Patients receiving tofacitinib had fewer enthesitis relapses following initial resolution after 1 or 3 months.

The monoclonal antibody guselkumab (Tremfya), which targets the p19 subunit of interleukin (IL)-23, was effective for treating the enthesitis and dactylitis components of psoriatic arthritis (PsA), ...